Table 4.

Sensitivity and specificity of creatinine‐corrected urinary laminin‐γ2 (Ln‐γ2/crn), nuclear matrix protein 22 (NMP22), bladder tumor antigen (BTA), according to tumor variable

Variable	No. of patients	Ln‐γ2/crn, %	NMP22, %	BTA, %
Tumor grade
Low	18	94.4/45.9	27.8/98.4	27.8/98.4
High	21	100.0/45.9	23.8/98.4	23.8/98.4
Tumor stage
Ta	21	95.2/46.0	23.8/98.4	23.8/98.4
T1	7	100.0/45.9	37.5/98.4	37.5/98.4
Concurrent CIS	14	100.0/45.9	21.4/98.4	28.6/98.4
Non‐concurrent CIS	25	96.0/45.9	28.0/98.4	24.0/98.4
Primary/recurrence
Primary	21	95.2/45.9	33.3/98.4	23.8/98.4
Recurrence	18	94.4/45.9	27.8/98.4	27.8/98.4

Values indicate sensitivity (%)/specificity (%). CIS, carcinoma in situ.